Speaker

W. Marston Linehan, NCI, NIH, USA
W. Marston Linehan

W. Marston Linehan, M.D. received his internship, residency and fellowship training Duke University Medical Center.  He began his career at the National Cancer Institute in 1982 with positions as Senior Investigator and Urologist-in-Charge, NCI.  He is Chief of the Urologic Oncology Branch at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.  He has had a long standing interest in identification of the genetic basis of cancer of the kidney.  By studying patients and families with kidney cancer, he and his colleagues identified the VHL gene for von Hippel-Lindau syndrome and showed that the VHL gene is also the gene for clear cell renal cell carcinoma.  He and his colleagues identified the gene for Hereditary Papillary Renal Carcinoma (MET oncogene, type I papillary renal carcinoma) the FLCN gene (Birt Hogg Dubé syndrome, chromophobe renal carcinoma), the gene for TFE3 kidney cancer and described the germline fumarate hydratase and succinate dehydrogenase B/C/D mutations in the North American families with hereditary leiomyomatosis renal cell carcinoma (HLRCC) and SDH-RCC and described five new diseases.  This work has provided the basis for the development of new therapeutic strategies for the different types of kidney cancer based on understanding the molecular pathway of the specific cancer genes associated with the different types of kidney cancer.  He and his colleagues have defined the methods for clinical management of kidney cancer associated with the hereditary forms of kidney cancer, von Hippel Lindau, Hereditary Papillary Renal Carcinoma and Birt Hogg Dubé syndrome and Hereditary Leiomyomatosis Renal Cell Carcinoma and Succinate Dehydrogenase Renal Cell Carcinoma.

« Go Back

Register Here Submit Abstract
Supporting Publications


Silver Sponsor
 


Awards